spacer
home > ebr > autumn 2018 > goal!
PUBLICATIONS
European Biopharmaceutical Review

GOAL!

Alnylam’s Onpattro is the first approved drug that treats disease by RNA interference – silencing gene expression. It is the culmination of a 15-year-long march by the company to develop and harness the enabling technologies necessary for successful commercialisation. Some commentators have called it a “clean sweep of efficacy and safety.”

The FDA views this breakthrough as part of a growing trend to treat disease by targeting root cause instead of treating symptoms. In this regard, RNA interference is complementary to other advanced therapeutic approaches. RNAi, like monoclonal antibodies, is dosedependent and can be modulated. Gene therapy, when it comes to fruition, is, in principle, permanent.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG to Showcase its Range of Capsules and Engineering Solutions at Supply Side West, Las Vegas

ACG, the only supplier in the world offering end-to-end manufacturing solutions for the pharmaceutical and the nutraceutical industries, will be exhibiting its wide range of Engineering and Capsules solutions at this year’s Supply Side West, Las Vegas. At ACG’s booth, the visitors will be able to see the synergies created with coupling ACG’s Capsules and Engineering products, thereby leveraging the many benefits of integrated manufacturing.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

Clinical Trial Supply Europe 2019

13-14 March 2019, Milan, Italy

Following on from our largest and most engaging meeting to date, Clinical Trial Supply Europe will be returning to Milan for its 20th year in 2019! The 19th annual edition welcomed pharmaceutical companies across Europe who got together to share knowledge and issues regarding clinical trial supplies, both with regards to operational and technological challenges. Over the two days, delegates discussed issues which affected their business in our dedicated operational and technological streams.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement